NCT02178098View on ClinicalTrials.gov

Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

June 16, 2014

Primary Completion Date

May 22, 2015

Study Completion Date

May 22, 2015

Conditions
HypercholesterolemiaHypertension
Interventions
DRUG

ETC-1002

ETC-1002 capsules taken once daily

DRUG

Placebo

Placebo capsules taken once daily

Trial Locations (43)

13760

Endwell

19335

Downingtown

28401

Wilmington

29464

Site 1, Mt. Pleasant

Site 2, Mt. Pleasant

29681

Simpsonville

32127

Port Orange

32720

DeLand

32765

Oviedo

33012

Hialeah

33026

Pembroke Pines

33029

Pembroke Pines

33306

Fort Lauderdale

35209

Birmingham

35662

Muscle Shoals

38654

Olive Branch

42003

Paducah

44094

Willoughby Hills

44124

Lyndhurst

45219

Cincinnati

45245

Cincinnati

45246

Cincinnati

46260

Indianapolis

53142

Kenosha

53719

Madison

59701

Butte

60031

Gurnee

60607

Chicago

74136

Tulsa

75230

Dallas

75234

Dallas

77036

Houston

78404

Corpus Christi

83646

Meridian

84107

Salt Lake City

84124

Salt Lake City

85224

Chandler

85306

Glendale

89123

Las Vegas

90057

Los Angeles

97404

Eugene

04210

Auburn

08009

Berlin

Sponsors

Collaborators (1)

Medpace, Inc.
All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

Esperion Therapeutics, Inc.

INDUSTRY

NCT02178098 - Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension | Biotech Hunter | Biotech Hunter